Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 480.00
Bid: 480.50
Ask: 490.00
Change: -5.00 (-1.03%)
Spread: 9.50 (1.977%)
Open: 480.00
High: 480.00
Low: 480.00
Prev. Close: 485.00
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

10 Oct 2023 07:00

RNS Number : 4807P
Treatt PLC
10 October 2023

10 October 2023

TREATT PLC

("Treatt" or "the Group")

Trading update for the year ended 30 September 2023

Profit growth returns with resilient revenue performance

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, today publishes a trading update for the year ended 30 September 2023 ("FY23").

HIGHLIGHTS:

· Resilient revenue growth of 5% (3% in constant currency) at c.£147m (FY22: £140m), despite industry de-stocking headwinds

· FY23 profit before tax and exceptional items expected to be in line with Board expectations of c.£17m, up by c.11% on FY22

· Successful pricing actions to recover raw material inflation

· China and Coffee growth in line with expectations

· Strong cost disciplines and other self-help measures mitigating the impact of customer destocking

· Year-end net debt of c.£10.5m (FY22: £22.4m), reflecting record cash generation

· UK site transition now complete, providing strong platform for growth

FY23 Performance

Revenue for the year is anticipated to be c.£147m (FY22: £140m), up 5% (3% at constant currency) despite the challenging macro environment and sector destocking, particularly in H2. Sales price increases were successfully implemented to offset raw material price inflation reflecting value-add nature of Treatt's product portfolio.

Core categories, which include Citrus, Synthetic Aromas and Herb Spices & Florals have grown by 1% (revenue: c.£98m). Premium categories, which include Tea, Health & Wellness, Fruit & Vegetables, are in line with the prior year (revenue: c.£33m). New markets, which include Coffee, China and Treattzest citrus, have grown by 60% (revenue: c.£16m).

The Board expects to report profit before tax and exceptional items for FY23 of c.£17m which is c.11% ahead of prior year (FY22: £15.3m), with strong cost discipline and other self-help measures allowing more sales growth to convert to profit.

Operational developments

After substantial investment in our people and production facilities over the last five years, we are well-placed to support the next phase of growth, and do not anticipate any significant increases to the cost base, other than inflation. The group headcount has reduced by 14% since September 2022.

Having implemented a revised currency management strategy, providing increased visibility and controls over our currency exposures, foreign exchange impacts in the year were minimal.

Balance sheet

The Group ended the year with net debt of c.£10.5m (FY22: £22.4m). With the transition to the new site now complete, capital expenditure has returned to normalised levels. The Group completed refinancing of the UK bank facility for £25m with HSBC with a minimum term of three years.

Daemmon Reeve, CEO of Treatt, commented:

"We delivered positive growth in sales and profit for the year, reflecting the significant price increase programme and ongoing resilience in our beverage end markets. Revenues in the second half of the year were impacted by certain customers reducing inventories in response to interest rate rises. However, we are seeing some early signs of a reversal of this temporary destocking effect, and have also been able to mitigate the effect of this impact with strong cost discipline and other self- help measures. With our unique value-add products, in conjunction with the new site transition now complete, we are confident in Treatt's long-term prospects."

Treatt's results for the year ended 30 September 2023 are expected to be announced on 28 November 2023.

Enquiries:

Joint Brokers

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

Peel Hunt LLP +44 (0) 20 7418 8900

George Sellar

Mike Burke

Financial PR

MHP +44 (0) 20 3128 8789

Tim Rowntree

Eleni Menikou

Catherine Chapman

About the Group

Treatt is a global, independent manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the flavour, fragrance and multinational consumer product industries, particularly in the beverage sector. Renowned for its technical expertise and knowledge of ingredients, their origins and market conditions, Treatt is recognised as a leader in its field.

The Group employs approximately 400 staff in Europe, North America and Asia and has manufacturing facilities in the UK and US. Its international footprint enables the Group to deliver powerful and integrated solutions for the food, beverage and fragrance industries across the globe.

For further information about the Group, visit www.treatt.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTKKLFBXBLFFBE
Date   Source Headline
25th Jan 20181:47 pmRNSHolding(s) in Company
29th Dec 20177:00 amRNSVoting Rights and Captial
22nd Dec 20179:01 amRNSHolding(s) in Company
21st Dec 20173:23 pmRNSHolding(s) in Company
19th Dec 20173:46 pmRNSDirector/PDMR Shareholding
19th Dec 20173:20 pmRNSHolding(s) in Company
18th Dec 20173:41 pmRNSResult of General Meeting
14th Dec 201710:41 amRNSAnnual Financial Report
6th Dec 20175:04 pmRNSHolding(s) in Company
1st Dec 20174:16 pmRNSBlock Listing Six Monthly Return
1st Dec 20177:00 amRNSTotal Voting Rights
28th Nov 20177:00 amRNSPlacing to raise £21.6 million
28th Nov 20177:00 amRNSFinal Results
10th Nov 201712:34 pmRNSHolding(s) in Company
2nd Oct 20177:00 amRNSTrading Update
29th Sep 20175:14 pmRNSTotal Voting Rights
26th Sep 20178:54 amRNSHolding(s) in Company
21st Sep 201712:23 pmRNSHolding(s) in Company
21st Aug 201711:09 amRNSDirector/PDMR Shareholding
2nd Aug 20175:07 pmRNSTotal Voting Rights
20th Jul 20171:50 pmRNSDirector/PDMR Shareholding
5th Jun 20171:35 pmRNSBlock Listing Six Monthly Return
23rd May 20179:30 amRNSBlock Listing Application
11th May 20174:05 pmRNSHolding(s) in Company
11th May 20174:01 pmRNSDirector/PDMR Shareholding
10th May 20172:53 pmRNSHolding(s) in Company
9th May 20177:00 amRNSHalf-year Report
5th Apr 20174:41 pmRNSHolding(s) in Company
3rd Apr 20175:25 pmRNSDirector/PDMR Shareholding
31st Mar 20173:57 pmRNSTotal Voting Rights
30th Mar 20177:00 amRNSTrading Statement
27th Mar 20179:30 amRNSHolding(s) in Company
24th Mar 20173:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20174:50 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSDirector/PDMR Shareholding
23rd Feb 20177:00 amRNSTrading Statement
20th Feb 20174:03 pmRNSDirector/PDMR Shareholding
14th Feb 20178:15 amRNSHolding(s) in Company
10th Feb 20179:41 amRNSHolding(s) in Company
1st Feb 20172:19 pmRNSDirector/PDMR Shareholding
30th Jan 20175:58 pmRNSNotification of a Transaction of a Director
27th Jan 20174:42 pmRNSResult of AGM
27th Jan 20177:15 amRNSTrading Statement
30th Dec 20167:00 amRNSTotal Voting Rights
30th Dec 20167:00 amRNSAnnual Information Update
22nd Dec 20163:11 pmRNSUpdate on Site Relocation
20th Dec 201610:26 amRNSDirector/PDMR Shareholding
13th Dec 20161:11 pmRNSNotification of Transactions of Directors
9th Dec 20163:05 pmRNSAnnual Financial Report
5th Dec 20164:35 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.